Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Jefferies Financial raised the target price of Eli Lilly and Co. to $1015.
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Jefferies Maintains Buy on Eli Lilly and Co, Raises Price Target to $957
Eli Lilly: Goldman Sachs raised the target price from $740 to $785
Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915